Published in final edited form as:

J Med Chem. 2012 January 12; 55(1): 327–341. doi:10.1021/jm201230z.

Piperazine-2,3-dicarboxylic acid Derivatives as Dual Antagonists of NMDA and GluK1-Containing Kainate Receptors

Mark W. Irvine^{1,#}, Blaise M. Costa^{3,#}, Daniel Dlaboga¹, Georgia Culley¹, Richard Hulse², Caroline L. Scholefield¹, Palmi Atlason¹, Guangyu Fang¹, Richard Eaves¹, Richard Morley¹, Maria B. Mayo-Martin¹, Mascia Amici¹, Zuner A. Bortolotto¹, Lucy Donaldson², Graham L. Collingridge¹, Elek Molnár¹, Daniel T. Monaghan^{3,#}, and David E. Jane^{1,*,#}

¹MRC Centre for Synaptic Plasticity, University of Bristol, Medical Sciences Building, University Walk, Bristol, BS8 1TD, UK

²School of Physiology and Pharmacology, University of Bristol, Medical Sciences Building, University Walk, Bristol, BS8 1TD, UK

³Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska 68198-6260 U.S.A

Abstract

Competitive *N*-methyl-D-aspartate receptor (NMDAR) antagonists bind to the GluN2 subunit, of which there are four types (GluN2A-D). We report that some *N*¹-substituted derivatives of cis-piperazine-2,3-dicarboxylic acid display improved relative affinity for GluN2C and GluN2D versus GluN2A and GluN2B. These derivatives also display subtype-selectivity among the more distantly related kainate receptor family. Compounds **18i** and (–)-**4** were the most potent kainate receptor antagonists and **18i** was selective for GluK1 versus GluK2, GluK3 and AMPA receptors. Modeling studies revealed structural features required for activity at GluK1 subunits and suggested that S674 was vital for antagonist activity. Consistent with this hypothesis, replacing the equivalent residue in GluK3 (alanine) with a serine imparts **18i** antagonist activity. Antagonists with dual GluN2D and GluK1 antagonist activity may have beneficial effects in various neurological disorders. Consistent with this idea, antagonist **18i** (30 mg/Kg i.p.) showed antinociceptive effects in an animal model of mild nerve injury.

Introduction

Ionotropic glutamate receptors (iGluRs) are L-glutamate-gated ion channels that mediate fast synaptic transmission in the central nervous system (CNS). There are three groups of iGluRs named after compounds by which they are selectively activated: AMPA ((*S*)-2-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid), kainate ((2*S*,3*S*,4*S*)-3-carboxymethyl-4-isopropenyl-pyrrolidine-2-carboxylic acid) and NMDA (*N*-methyl-D-aspartic acid) receptors.¹ Kainate receptors (KARs) are tetrameric assemblies of GluK1-5 subunits (IUPHAR nomenclature of the receptors that were previously known as GluR5-7, KA1 and KA2).² AMPA receptors (AMPA receptors) are tetrameric assemblies of a combination of GluA1-4 subunits (IUPHAR nomenclature of the receptors that were previously known as GluR1-4 or GluRA-D)², while NMDAR tetramers can be assembled from GluN1, GluN2A-

*To whom correspondence should be addressed. Phone: +44 (0)117 3311409. Fax: +44 (0)1173312288. david.jane@bristol.ac.uk^{1a}.

[#]MI and BMC contributed equally as first authors and DEJ and DTM as senior authors.

Supporting Information Available.

Experimental procedures and elemental analyses for intermediates and additional final compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

D and in some areas of the CNS, GluN3A and GluN3B subunits (IUPHAR nomenclature of the receptors that were previously known as NR1, NR2A-D and NR3A and NR3B).^{1,2,3}

NMDARs have been the subject of intense investigations into the development of antagonists due to the implication of these receptors in neurological disorders such as epilepsy and chronic pain and neurodegenerative disorders such as ischemia, Alzheimer's and Parkinson's diseases.⁴ Antagonists interacting with the glutamate binding site on GluN2 subunits, the glycine binding site on GluN1 subunits, the ion channel pore and the N-terminal domain of the GluN2B subunit have been developed.^{1,2,3} Most antagonists interacting at the orthosteric glutamate binding site on GluN2 subunits such as **1**, **2** and **3** (Figure 1) display the following rank order of affinity GluN2A>GluN2B>GluN2C>GluN2D.³ We have reported that piperazine-2,3-dicarboxylic acid derivatives such as ($\pm$)-**4** and **5** (Figure 1) show a different rank order of affinity: GluN2D~GluN2C>GluN2B>GluN2A.^{5,6} Negative allosteric modulators have been reported that have greater GluN2 subunit selectivity than that reported for competitive antagonists. For example, **6** binds selectively to the N-terminal domain of GluN2B⁷ and **7**⁸ and **8**⁹ (Figure 1) selectively block GluN2C/GluN2D versus GluN2A and GluN2B.

The first antagonists with significant activity at KARs were from the quinoxalinedione class of compounds, such as the potent AMPAR antagonist 2,3-dihydroxy-6-nitro-7-sulphamoylbenzo(f)quinoxaline (**9**) (Figure 1).¹⁰ Quinoxalinediones were not useful as pharmacological tools for KARs, as they also antagonized AMPARs. More recently a series of decahydroisoquinolines, such as **10** (Figure 1), have been reported as selective GluK1 containing KAR antagonists.^{11,12} These antagonists displayed selectivity for GluK1 versus GluK2-containing KARs and AMPARs and were therefore used to provide evidence to support the role of GluK1 in synaptic plasticity in the mossy fiber to CA3 region of the hippocampus and in a number of CNS disorders such as chronic pain, epilepsy, ischaemia and migraine.^{2b,11,12} The activity of decahydroisoquinolines on GluK3 is not well established, as only **10** (Figure 1) has been tested on GluK3 to date. Compound **10** was found to have no activity on homomeric GluK3 at the concentration at which it is used to block GluK1 in physiological experiments.¹³

We have reported that derivatives of the natural product willardiine, such as **11** and **12** (Figure 1), are selective GluK1-containing KAR antagonists.¹⁴ Compounds from this series have been used to implicate GluK1-containing KARs in the induction of long-term potentiation (LTP) in the mossy fiber to CA3 pathway in the hippocampus and in short term recognition memory.¹⁵ Derivatives of the natural product willardiine, such as **11** and **12**, are selective for GluK1-containing receptors over GluK2¹⁴, but these compounds also potentially antagonize homomeric GluK3 receptors.¹³

Two N¹-substituted piperazine-2,3-dicarboxylates **13** and **14** (Figure 1) have been shown to be broad spectrum iGluR antagonists that bind to both NMDARs and KARs.¹⁶ Herein we report the synthesis and pharmacological characterization of a new series of analogues of **13** and **14**, which show moderate selectivity for GluN2C/GluN2D versus GluN2A/GluN2B and in the case of one of the more potent GluK1 antagonists identified in this study, excellent selectivity for GluK1 versus GluK2 and GluK3. Molecular modeling studies using the X-ray crystal structure of the antagonist bound form of the ligand binding domain (LBD) of GluK1 have been used to investigate the binding modes of some compounds in GluK1. The proposed GluK1 binding model was then tested by site-directed mutagenesis. Given that both GluK1 and GluN2D have been implicated in neuropathic pain,^{4b,11e,f,12b} we tested a compound that is a dual antagonist of GluN2D and GluK1 in an animal model of mild nerve injury to assess antinociceptive activity.

Results

Chemistry

A series of N¹-substituted piperazine-2,3-dicarboxylic acid derivatives (**18a–m**) were synthesized by reacting various acid chlorides (**16a–m**) with the cis-isomer of **17** under modified Schotten-Baumann conditions (Scheme 1).⁶ The acid chlorides (**16a–m**) were prepared from the corresponding carboxylic acids (**7**, **15a–m**) by treatment with excess thionyl chloride. The only exception to this was **16l** which was purchased commercially. Carboxylic acids **15a**, **15b**, **15e**¹⁷, **15f**¹⁸, **15j**, and **15m** were either available commercially or synthesized via published procedures. The naphthyl and biphenyl carboxylic acid compounds (**19** and **20**) were synthesized via base hydrolysis of the corresponding esters (**18e** and **18m**). Hydrogenation of the alkyne linker in **18k** afforded phenethyl derivative **21** (Scheme 2).

6-Iodo-2-naphthoic acid (**15c**) has previously been synthesized from N-acetyl-2-naphthylamine via a time consuming seven step route.¹⁹ However, by utilizing an aromatic Finkelstein reaction to convert methyl 6-bromo-2-naphthoate (**22**) to its corresponding iodo analogue (**23**) and then hydrolysing the ester we were able to generate **15c** in only 2 steps (Scheme 3). Suzuki coupling between **22** and phenylboronic acid afforded ester **24** which was subsequently hydrolysed to **15d** (Scheme 3). Sonogashira coupling followed by a haloform reaction was employed to convert 4-iodoacetophenone (**25**) to acetylene acid **15k** (Scheme 3).

The 3-acetyl derivatives of 9-chloro and 9-bromophenanthrene (**27** and **28**) were synthesized by Friedel-Crafts acylation as described previously.^{20,21} Unfortunately, attempts to utilize the same conditions to synthesize the 3-acetyl derivative of 9-iodophenanthrene failed and led only to the isolation of a black tar. Attempts to modify the reaction conditions by using aluminium iodide instead of aluminium chloride or acetic anhydride instead of acetyl chloride led only to the same outcome. Consequently, we employed an aromatic Finkelstein reaction²² to convert 3-acetyl-9-bromophenanthrene (**28**) to its corresponding 9-iodo analogue (**29**). The acetyl compounds (**27–29**) were conveniently converted to the desired phenanthrene acids (**7**, **15g**, **15h**) by reaction with sodium hypobromite in a modified haloform reaction (Scheme 4).

Resolution of (±)-**4** was achieved by forming diastereomeric salts with the individual enantiomers of 1-phenethylamine (**32** and **33**) (Scheme 5). In each case, the isolated diastereomeric salts were crystallized to constant rotation to provide the pure diastereoisomers (**30** and **31**). These were then individually dissolved in THF/H₂O and acidified with aqueous hydrochloric acid to afford the free acids of each enantiomer ((-)-**4** and (+)-**4**, Scheme 5) in good yield.

Electrophysiological assays on Recombinant Rat NMDAR subtypes expressed in *Xenopus* Oocytes

We have reported previously that piperazine-2,3-dicarboxylic acids substituted at the N¹ position with bulky aromatic substituents show an unusual pattern of GluN2 subunit selectivity.^{5,6} The vast majority of competitive antagonists, such as compounds **1** and **2** (Figure 1), display the following rank order of affinity: GluN2A > GluN2B > GluN2C > GluN2D.³ However, compounds (±)-**4** and **5** (Figure 1) display the opposite rank order of affinity: GluN2D ~ GluN2C > GluN2B > GluN2A, though the degree of separation between GluN2 subunits is only up to ~10-fold. We have proposed that this altered selectivity is due to the large phenanthrene group extending out of the highly conserved glutamate binding pocket and interacting with subunit-specific elements in the receptor.^{5,6,23} We have synthesized several novel compounds with modifications to the phenanthrene ring to gain

more insight into the structural requirements for GluN2 subunit selectivity, with the focus being on developing GluN2D subunit selective competitive antagonists. We also sought to define their actions at the more distantly related KAR family. The new compounds ((-)-**4**, (+)-**4**, **18a-d**, **18f**, **18g-i**, **19-21**, Tables 1 and 2) were tested on GluN1a in combination with each of the four genetically distinct subunits, GluN2A-D expressed in *Xenopus* oocytes in an electrophysiological assay using two-electrode voltage clamp. The IC₅₀ values that were determined for the ability of the compounds to block a response evoked by 10 μ M L-glutamate and 10 μ M glycine were converted to K_i values to take into account the differences in agonist potency for the individual GluN2 subtypes.

When the individual enantiomers of ($\pm$)-**4** were tested, it was found that the high affinity GluN2D binding resided in the (-)-**4** isomer with the (+)-**4** isomer displaying 50-fold lower affinity for GluN2D (Table 2). However, (-)-**4** showed no improvement in GluN2D selectivity compared to ($\pm$)-**4**. We have demonstrated previously that a 3-ring aromatic substituent is required for optimal affinity and selectivity for GluN2D.^{5,6} A phenanthrene ring attached at the 3-position to the carbonyl group, as in **5** (Table 2), is most favored for GluN2D subunit selectivity, albeit with reduced GluN2D affinity compared to ($\pm$)-**4**.^{5,6} For a series of 9-halo-substituted phenanthrene derivatives (**18g-i**, Table 2) of **5** the rank order of affinity for each of the four GluN2s was I > Br > Cl > H. The most GluN2D selective compounds were the parent compound **5** and the 9-bromo derivative **18h**. These compounds showed 10- and 7-fold selectivity for GluN2D versus GluN2A and GluN2B, respectively, but showed only two-fold selectivity for GluN2D versus GluN2C. Thus, substitution at the 9-position has little impact on GluN2D affinity but GluN2D selectivity varies with the nature of the substituent. Replacement of the phenanthrene ring of ($\pm$)-**4** with an anthracene ring to give **18j** did not improve affinity or selectivity for GluN2D (Table 2).

To determine whether a linker could replace the middle ring of ($\pm$)-**4** we tested analogues in which the first and last benzene rings were separated with an acetylene (**18k**), ethylene (**21**) or diazene (**18l**) linker (Table 1). These substitutions were found to be detrimental; each of these compounds had low affinity for GluN2D, with **21** having much reduced GluN2D potency compared to ($\pm$)-**4** (**21** (100 μ M) showed only ~10% antagonism of agonist induced effects on GluN2D). **18l** and **18k** showed partial GluN2D selectivity, with ~10-fold selectivity for GluN2D versus GluN2A but they did not differentiate between GluN2D and GluN2B or GluN2C. Replacement of the first phenyl ring of ($\pm$)-**4** with an ethylene spacer to give **18f** reduced GluN2D affinity and selectivity (Table 1).

A series of 6-substituted naphthalene derivatives (**18a-d**, **19**, Table 1) were tested to determine if the 6-substituent could replace the third benzene ring of ($\pm$)-**4**. The rank order of affinity of the 6-substituted naphthalene derivatives for GluN2D was: I > Br > Ph > F > H > CO₂H. The higher affinity observed for naphthalene derivatives bearing lipophilic substituents compared to polar substituents suggests that the 6-substituent is in a spacious hydrophobic environment in the GluN2D ligand binding site. A similar marked lowering in GluN2D affinity was observed when a 4'-carboxy substituent was added to the biphenyl derivative **34b** leading to compound **20** (Table 1). A number of these compounds had similar affinity for GluN2D to that observed for phenanthrene substituted compounds such as **5** and its derivatives (Table 2), suggesting that the third phenyl ring does not have a major impact on GluN2D affinity. However, the presence of the third phenyl ring improved GluN2D selectivity (e.g. **5** (Table 2) shows much greater GluN2D selectivity than **18b** (Table 1)), mainly by reducing affinity for GluN2A and GluN2B. Amongst the 6-naphthyl derivatives only **18d** (Table 1) showed GluN2D selectivity, with only 30–37% antagonism of GluN2A and GluN2B observed when tested at 100 μ M. However, this compound did not discriminate between GluN2C and GluN2D. It was not possible to obtain K_i values for antagonism of GluN2A and GluN2B by **18d** to obtain a good estimate of selectivity due to poor solubility

at higher concentrations. At a concentration of 300 μM in the electrophysiological recording buffer at room temperature, the compound displayed visible light scattering and thus the compound was considered insoluble at high concentrations.

Calcium Fluorescence Assays on Human KAR Subtypes

Two benzoylpiperazine-2,3-dicarboxylic acid derivatives **13** and **14** (Figure 1) have been reported to be more potent as antagonists of KARs than NMDARs. However, the interpretation of these experiments is complicated by the use of non-selective agonists in the assays.^{2b,16} To investigate the potential KAR antagonist activity of a range of N¹-substituted piperazine-2,3-dicarboxylic acids, including the newly synthesized compounds ((-)-**4**, (+)-**4**, **18a-d**, **18f**, **18g-l**, **19-21**) and those reported previously (($\pm$)-**4**, **5**, **34a-h**) (Tables 1 and 2), they were tested on human recombinant GluK1 receptors expressed in human embryonic kidney 293 (HEK293) cells. The IC₅₀ values that were determined for the ability of the compounds to block an increase in Ca²⁺-stimulated fluorescence evoked by 100 μM L-glutamate were converted to K_B values (Tables 1 and 2). Many of the compounds had similar antagonist potency on GluK1 and GluN2D while other compounds displayed selectivity for GluK1 versus GluN2D or >30-fold selectivity for GluN2D versus GluK1.

Compounds with a 3-ringed aryl substituent were found to be the most potent GluN2D antagonists; however, this feature was less important for activity on GluK1. Thus, ($\pm$)-**4** (Table 2) had similar affinity for GluK1 to the biphenyl derivative **34b** and only 6-fold higher affinity than the naphthyl derivative **34a** (Table 1). The interaction of ($\pm$)-**4** with GluK1 was stereoselective with ($\pm$)-**4** displaying 8-fold higher affinity than the trans-isomer (**34d**) and the (-)-**4** enantiomer having 27-fold higher affinity than the (+)-**4** enantiomer (Table 2). However, the stereoselectivity for binding to GluK1 was not as great as that observed for the interaction of these isomers of ($\pm$)-**4** with GluN2D. (-)-**4** was the most potent GluK1 antagonist tested. However, it had higher affinity for GluN2D and displayed ~30-fold selectivity for GluN2D versus GluK1. 7-Bromo substitution of the phenanthrene ring of ($\pm$)-**4** to give **34e** did not change GluK1 affinity (Table 2). An analogue of ($\pm$)-**4** with a saturated middle ring (**34g**) and its 9-bromo derivative (**34h**) had similar GluK1 affinity to that determined for the corresponding unsaturated derivatives (Table 2). Replacement of the carbonyl linker of ($\pm$)-**4** with a CH₂ group to give **34f** (Table 2) reduced GluK1 affinity 5-fold probably due to increased rotational freedom. The anthracene substituted derivative **18j** had only two-fold lower affinity for GluK1 compared to ($\pm$)-**4** (Table 2), suggesting that the pocket accommodating these bulky aromatic rings in the LBD of GluK1 is not as tight as that in GluN2D or that the aromatic ring is projecting out of the GluK1 LBD. These conclusions are backed up by the observation that the 3-phenanthryl derivative, **5** has similar affinity to that observed for ($\pm$)-**4** and **18j** (Table 2). Addition of a halo substituent to the 9-position of the phenanthrene ring of **5** resulted in the following rank order of affinity: I > Br > H > Cl, suggesting that the 9-position substituent is accommodated by a spacious hydrophobic pocket. The 9-bromo derivative **18h** displays ~9-fold selectivity for GluN2D versus GluK1 but the 9-iodo derivative **18i** has almost equal affinity for these two subunits (Table 2).

In the 6-substituted naphthyl series (**18a-d**, **19**, Table 1) the following rank order of affinity was observed on GluK1: Ph > I > Br > H > CO₂H ~ F, suggesting that there is a spacious hydrophobic pocket in the vicinity of the 6-substituent that does not accommodate polar substituents. As was observed in the SAR study on GluN2D the presence of the third aromatic ring in **5** (Table 2) and its derivatives has only a weak enhancing effect on GluK1 affinity when compared to the corresponding 6-substituted naphthyl analogue (e.g. **18i** (Table 2) has only 1.7-fold higher affinity for GluK1 compared to **18c** (Table 1)). The antagonist **18d** (Table 1) that showed reasonable selectivity for GluN2C/GluN2D versus GluN2A/GluN2B had a similar affinity for GluK1 to that observed for GluN2D.

Replacement of the carbonyl linker of the biphenyl derivative **34b** with a sulphonyl group to give **34c** markedly reduces GluK1 affinity such that this compound shows selectivity for GluN2D versus GluK1 (Table 1). Interestingly, 4'-carboxy substitution of **34b** to give **20** markedly reduces GluN2D affinity but only reduces GluK1 affinity 5-fold and therefore **20** is selective for GluK1 versus GluN2D (Table 1). The extent of this selectivity could not be determined due to poor water solubility at higher concentrations. Replacement of the first phenyl ring of ($\pm$)-**4** by an ethylene spacer to give **21** reduces GluK1 affinity 9-fold (Table 1). Analogues of cis-**34b** where the phenyl rings are joined by an acetylene (**18k**), ethylene (**21**) or diazene (**18l**) spacer had approximately 2-fold lower affinity for GluK1 compared to the parent compound (Table 1). Thus, **18k** and **18l** had similar affinities for GluK1 and GluN2D.

The compounds that displayed the highest affinity for GluK1 were also tested as antagonists of GluK2 receptors. A number of compounds in this series (($\pm$)-**4**, **5**, **18c**, **18d**, **18h-j**, **18k**, **18l**, ($-$)-**4**, **34b**, **34c** and **34g**) show selectivity for GluK1 versus GluK2, as they had no GluK2 antagonist activity when tested at a concentration of 100 μ M (Tables 1 and 2).

Electrophysiological characterization of the activity of **18i** on Human KAR subtypes and native AMPARs

Compound **18i** was one of the most potent of the GluK1 antagonists that were identified in the Ca^{2+} fluorescence assay described above. Due to the rapid and concanavalin A insensitive desensitization of GluK3 receptors upon agonist application, it was not possible to use the Ca^{2+} fluorescence assay to test compounds on GluK3.¹³ Therefore, we tested **18i** across GluK1-3 to assess KAR subunit selectivity using an electrophysiological assay that relies on fast application of L-glutamate. In these assays **18i** was a moderately potent antagonist of GluK1 with an IC_{50} value of 0.65 μ M (95% confidence intervals: 0.27 μ M – 1.7 μ M, $n=1-6$), a much weaker antagonist of GluK3 with an IC_{50} value of 81.3 μ M (95% confidence intervals: 40.5 μ M – 163 μ M, $n=3-8$) and had only weak activity on GluK2 (IC_{50} value > 100 μ M, $n=2$). Thus, **18i** has a >100-fold lower IC_{50} for GluK1 versus GluK3 and has only very weak antagonist activity on GluK2 (Figure 2A).

Compound **18i** showed no antagonist activity at a concentration of 100 μ M ($n=4$) in an electrophysiological assay on AMPAR mediated excitatory postsynaptic potentials (EPSPs) in the CA3 region of the hippocampus (Figure 2B). Thus, **18i** shows good selectivity for GluK1 versus GluK2, GluK3 and AMPARs.

Ligand docking into the LBD of GluK1

To investigate binding modes of some compounds in GluK1, we undertook a molecular modeling study in which the X-ray structure of the LBD of GluK1 in complex with the antagonist **11** (Figure 1) was used as a template.²⁴ Both enantiomers of each of ($\pm$)-**4** (Table 2), cis-**18c** (Table 1) and cis-**18i** (Table 2) were docked into the LBD of GluK1 using the Induced Fit workflow within Maestro, which carries out an initial docking using Glide, followed by side chain optimisation within 5 angstroms of ligand poses with Prime and then a more precise Glide docking in XP mode.²⁵ Only the 2*S*,3*R* isomer of **4** gave satisfactory poses in docking experiments with the LBD of GluK1 (Figure 3A). This is in agreement with the experimental observation that only the ($-$)-**4** enantiomer had high affinity for GluK1, suggesting that ($-$)-**4** has the 2*S*,3*R* configuration. This stereoselectivity was also observed in docking studies with the individual isomers of cis-**18c** and cis-**18i**.

Inspection of the binding modes of the 2*S*,3*R* enantiomers of **4**, **18c** and **18i** revealed that the piperazine-2,3-dicarboxylic acid nucleus of all ligands adopted the same set of interactions with residues in the LBD of GluK1 (Figure 3) and were similar to those previously reported

for interaction with the LBD of GluN2 subunits.²³ The carboxylate group at the 3-position of the piperazine ring forms ionic and hydrogen bond interactions with R508 and a hydrogen bond interaction with T503. The marked reduction in antagonist affinity of **18i** observed for GluK2 compared to GluK1 may be due in part to the switch from T503 in GluK1 to an alanine residue at the equivalent position in GluK2. The carboxylate group at the 2-position of the piperazine ring forms a hydrogen bond with the OH group of S674. This direct interaction may be a major reason for the observed GluK1 versus GluK2 and GluK3 selectivity of **18i**, as in the latter two subunits S674 is replaced by an alanine residue. The positively charged secondary amine forms a hydrogen bond with the carbonyl group of P501. The interaction of the secondary amino group and the carboxylate group adjacent to it in piperazine-2,3-dicarboxylic acid derivatives with residues in the LBD is similar to the way in which the α -amino and α -carboxylate groups of antagonists such as **12** (Figure 1) interact with residues in the X-ray crystal structure of the LBD of GluK1.^{24,26}

Inspection of the binding mode of the 2*S*,3*R* isomer of **4** (Figure 1) to the LBD of GluK1 reveals that the phenanthrene ring is projected straight out of the cleft between the two domains of the LBD towards S706 (Figure 3A). The position of the phenanthrene ring of **4** in the LBD of GluK1 is similar to that previously observed in the LBD of GluN2 subunits. A major reason for the lower affinity of the active enantiomer of **4** for GluK1 versus GluN2A-D is the scarcity of hydrophobic residues in GluK1 with which the phenanthrene ring of **4** can interact. The only hydrophobic residues available are V670, the CH₂ group of N705 and Y474, the latter being above the plane of the phenanthrene ring. This suggests that more of the phenanthrene ring is exposed to water when bound to GluK1 and so less binding energy is gained by loss of ordered water upon ligand binding to the LBD.

The binding mode of the 2*S*,3*R* isomer of **18c** (Table 1) in the LBD of GluK1 (Figure 3B) is similar to that observed in the LBD of GluN2A. However, the binding pocket for the naphthyl ring in GluK1 contains fewer residues, with only the side chains of K473, Y474 and A476 being available to form hydrophobic interactions. The explanation for the observed lower affinity of **18c** for GluK1 compared to GluN2A-D is therefore likely the same as that proposed for **4**. The rank order of affinity for GluK1 observed for 6-halonaphthyl derivatives was 6-I > 6-Br > 6-F (Table 1). This is consistent with the modeled interaction of **18c** with GluK1 where the larger iodo group is better able to form van der Waals interactions with K473, A476 and N484. The larger 6-phenyl group of **18d** (Table 1) is likely to be able to form more interactions with these residues and this may explain the slightly higher affinity of **18d** compared to **18c** for GluK1.

The modeled interaction of **18i** (Table 2) with the LBD of GluK1 (Figure 3C) was similar to that observed for **18c** (Table 1). There is less than a 2-fold increase in affinity for GluK1 when comparing **18i** to **18c**, so the extra phenyl ring is not contributing much to the binding energy and this is consistent with the modeled interaction of **18i**, as the distal phenyl ring is mainly pointing out into the solvent water. The 9-iodo group of **18i** occupies a similar position to the 6-iodo group of **18c** and so the observed rank order of affinity of 9-halo substituted derivatives: 9-I > 9-Br > 9-Cl (Table 2) can be explained in the same way as for 6-halo naphthyl derivatives.

Point mutation studies to investigate the binding of **18i** to GluK1 and GluK3

Modeling studies suggested that the GluK1 selectivity of **18i** (Table 2) may be at least in part due to the binding of the carboxylic acid at the 2-position of the piperazine ring to S674. Reduced binding of **18i** to GluK3 may be due to the switch from S674 in GluK1 to A660 in GluK3, as the alanine residue would not interact favorably with the 3-CO₂⁻ group of **18i**. We investigated this hypothesis by producing the A660S point mutant of rat GluK3. Immunoblot analysis³⁰ confirmed that the A660S mutation did not alter GluK3 protein

levels in HEK293 cells compare to wild type (not shown). In contrast to the low binding affinity observed on wild type GluK3, **18i** more potently inhibited [³H]kainate binding to the A660S point mutant of GluK3 (Figure 4), suggesting that it is the switch from S674 in GluK1 to A660 in GluK3 that is primarily responsible for the low affinity of **18i** for GluK3.

Effect of **18i** on nociceptive behavior in rats

Both GluN2D and GluK1 have been implicated in neuropathic pain.^{4b,11e,f,12b} We therefore investigated the antinociceptive activity of **18i**, a compound that is a dual GluN2D and GluK1 antagonist. In a mild nerve injury model, acute administration of **18i** completely reversed the drop in mechanical withdrawal threshold seen one week after injury (Figure 5A). Thermal hypersensitivity does not develop in animals with partial saphenous nerve ligation injury (PSNI)²⁷ but **18i** increased thermal withdrawal latency in these animals above baseline values (Figure 5B). **18i** also exerted antinociceptive effects in normal animals before nerve injury (not shown).

Discussion and Conclusions

NMDAR antagonists with selectivity for individual GluN2A-D subunits would have utility in determining the functions of these subunits in the CNS and may ultimately have therapeutic applications in a number of neurological disorders.⁴ Although, negative allosteric modulators with GluN2C/GluN2D selectivity have been reported^{8,9}, competitive antagonists with good selectivity for GluN2D have been harder to obtain, likely due to the high amino acid sequence homology amongst the orthosteric LBDs of GluN2A-D.

Structure- activity relationship studies on NMDA receptors

We have previously reported that N¹-aryl-substituted derivatives of cis-piperazine-2,3-dicarboxylic acid (**17**) (Scheme 1) are competitive NMDAR antagonists and that some of these antagonists have an unusual pattern of subunit selectivity, where they have greater selectivity for GluN2C or GluN2D-containing NMDARs compared to those containing GluN2A or GluN2B.^{5,6} However, the best compounds identified so far, such as **5** and **18h** (Table 2), only have at most a 10-fold selectivity for GluN2D versus GluN2A and GluN2B. We have therefore synthesized a new range of N¹-substituted analogues of **4** and **5** (Table 2) with the aim of gaining more knowledge of the structural requirements for optimal GluN2D selectivity. Of the new compounds that were tested, only **18d** (Table 1) showed greater GluN2D versus GluN2A selectivity compared to **5** and **18h**, however estimation of the K_i values for antagonist activity at GluN2A and GluN2B were hampered by poor water solubility of this compound at concentrations higher than 100 μM. Nonetheless, **18d** represents an important lead in developing competitive antagonists with GluN2C/GluN2D selectivity. Other compounds gave insights into the structural requirements for optimal interaction with GluN2D. For instance, we found that only the (–)-**4** enantiomer of (±)-**4** had potent antagonist activity at GluN2D subunits (Table 2) and our previously reported modeling studies suggest that this is the 2*S*,3*R* isomer.²³ Unfortunately, we have not been able to obtain confirmation of this configuration through X-ray crystallography, as suitable crystals of (–)-**4** have been impossible to obtain. We have shown that amongst 9-halo substituted derivatives of **5**, the 9-bromo derivative (**18h**) has greatest selectivity for GluN2D, though the 9-iodo derivative (**18i**) (Table 2) has highest affinity for this subunit. In the 6-halo substituted naphthyl series (**18a–d**, **19**, Table 1) the 6-iodo derivative (**18c**) had the highest affinity for GluN2D but showed little selectivity between the four GluN2 subunits, suggesting that the third phenyl ring of **18h** (Table 2) is important for increasing selectivity for GluN2D.

The ligand binding pocket in GluN2D includes two residues R437 (also present in GluN2C) and R737 (present only in GluN2D) that are not found in GluN2A or GluN2B. We have previously reported modeling and point mutation studies that suggested that the phenanthrene ring of **4** forms hydrophobic contacts with R737 and this likely explains the weak selectivity of this compound for GluN2D.²³ It is likely that similar contacts are made with R737 by the aromatic rings of **5**, **18d** and **18h** and this underlies their selectivity for GluN2D versus GluN2A and GluN2B. The fact that most compounds tested show no preference between GluN2C and GluN2D suggests that R437 may also play a role in forming hydrophobic interactions with the aromatic residues of these ligands.

Structure-activity relationship studies on kainate receptors

Two benzoyl-substituted derivatives **13** and **14** (Figure 1) have been shown to be non-selective antagonists of iGluRs²⁸ and were shown to block kainate-induced responses on isolated dorsal root C-fibers.^{16,28} KARs expressed on these dorsal root C-fibers have been reported to contain the GluK1 subunit.²⁹ We therefore tested the newly synthesized compounds and those whose activity on NMDARs we had reported previously, in a functional assay on recombinant human GluK1 receptors. All of the compounds except **34c** antagonized GluK1 receptors, with **18i**, **18d** and (–)-**4** being the most potent antagonists tested (Tables 1 and 2). Two of the more selective GluN2D antagonists **5** and **18h** have around 10-fold selectivity for GluN2D versus GluK1 (Table 2), however the 6-phenylnaphthyl derivative (**18d**, Table 1), which showed >10-fold selectivity for GluN2D versus GluN2A and GluN2B, had almost equal affinity for GluN2D and GluK1.

The difference in GluK1 activity between the carbonyl (**34b**) and sulphonyl (**34c**) (Table 1) linked biphenyl analogues is likely due to difference in geometry, which would lead to the biphenyl group probing different regions of the GluK1 LBD. Replacement of the carbonyl group with a sulphonyl linker may be a strategy for developing future derivatives with high affinity and selectivity for NMDARs versus GluK1. Two compounds **20** and **21** (Table 1) had little activity on NMDARs when tested at 100 μ M but **21** in particular had moderate antagonist activity at GluK1. These compounds may be leads for the development of more potent GluK1 selective antagonists.

The compounds with the most potent GluK1 antagonist activity were also tested on recombinant human GluK2 receptors but none of these compounds were found to have antagonist activity (Tables 1 and 2). One compound, **18i** (Table 2) was tested in electrophysiological assays on HEK293 cells individually expressing GluK1, GluK2 and GluK3. In these assays, **18i** was found to be a relatively potent GluK1 antagonist but had much weaker effects on GluK3 and little or no effect on GluK2 (Figure 2A). Thus, **18i** showed greater selectivity for GluK1 versus GluK3 (>100-fold difference in IC₅₀ values) compared to our previously reported GluK1 antagonists **11** and **12**¹³ (Figure 1).

Modeling and point mutation studies

Modeling studies suggested that the piperazine-2,3-dicarboxylic acid moiety of (–)-**4**, **18c** and **18i** bound to the LBD of GluK1 in a similar manner to which we have previously proposed for GluN2A-D.²³ The binding mode adopted by (–)-**4**, **18c** and **18i** in the LBD of GluK1 is unique to this class of compounds. The distal carboxylate of the decahydroisoquinoline and willardiine based antagonists binds deep in the S2 domain of the LBD of GluK1 and it is the spanning of the S1 and S2 domains in the LBD that underlies the foot in the door mechanism of antagonism.²⁶ Compounds (–)-**4**, **18c** and **18i** have a short inter-acidic group chain length and cannot reach the deep binding site in the S2 domain that is accessed by the distal acidic group of the decahydroisoquinoline and willardiine based antagonists. Compounds (–)-**4**, **18c** and **18i** produce their antagonist activity by a different

mechanism, as in this case the bulky aromatic substituent blocks the closure of the LBD (Figure 3A–C). A key observation from the modeling study was that S674 in GluK1 was involved in the binding of the carboxylate group at the 2-position of the piperazine ring. We hypothesized that this may underlie the GluK1 versus GluK2 and GluK3 selectivity of **18i**, as the latter two subunits have an alanine residue at the position corresponding to S674 in GluK1 and therefore cannot form a hydrogen bond with the carboxylate group at the 2-position of the piperazine ring of **18i**. Evidence to support this theory came from the observation that although **18i** had weak activity on wildtype GluK3, it had similar activity on the A660S GluK3 point mutant to that observed on GluK1 (Figure 4). It was not possible to test **18i** on the S674A GluK1 point mutant, as both mutant and wildtype GluK1 had very low expression levels when transiently transfected into HEK293 cells, as was evident from the very low specific binding of [³H]kainate. Thus, further studies are needed to provide more definitive evidence for the role of S674 in determining the selectivity of **18i** for GluK1 versus GluK2 and GluK3, such as point mutation studies on GluK2 and the acquisition of high resolution crystal structures. The presence of an alanine at position 487 in GluK2 may also contribute to the very low affinity of **18i** for GluK2. In GluK1 and GluK3, this residue is replaced by a threonine residue which makes a hydrogen bond contact with the carboxylate group at the 3-position of the piperazine ring of **18i**. Replacement of this threonine by an alanine would prevent this interaction. Similar reasoning was used to explain the low affinity of willardiine based antagonists, such as **11**, for GluK2.³⁰

Compound **18i** is selective for KARs versus AMPARs

Compound **18i** was found to be selective for GluK1 versus AMPARs, as it had no effect on AMPARs expressed in the hippocampus (Figure 2B). The lack of effect of **18i** on AMPARs appears to be more general, as we have previously reported that **5**, **18h**, **18k** and **18l** (Tables 1 and 2) were only very weak inhibitors of [³H]AMPA binding in competition binding assays.^{5c} In the same study we found that 100 μ M **5**, **18h**, **18k** and **18l** inhibited [³H]kainate binding only 10 – 20% but this assay detects activity on multiple KAR subunits and there is a relatively low abundance of GluK1 compared to other KAR subunits in whole brain or forebrain homogenates.³⁰ Thus, **18i** is a selective GluK1 antagonist that may be useful to study the function of KARs containing this subunit, as long as its NMDAR antagonist activity does not interfere. One application could be in the study of NMDAR independent LTP in the CA3 region of the hippocampus, which is known to be dependent on KARs.^{2b}

Antinociceptive effect of **18i** in an animal model of nerve injury

GluK1 antagonists have been shown to modulate nociceptive function in acute nociceptive and inflammatory models.^{11e} The location of GluK1 on the non-peptidergic population of nociceptive afferents led to the hypothesis that GluK1 antagonists might be effective modulators of neuropathic, as opposed to inflammatory pain.³¹ Likewise, GluN2D-containing receptors have a specific role in neuropathic pain; GluN2D knockout mice do not display enhanced pain responses in the sciatic nerve ligation model.^{4b} Hence, a dual GluK1/GluN2D selective agent would be predicted to have enhanced antinociceptive properties. We have shown that **18i**, administered by intraperitoneal (i.p.) injection, in an animal model of mild nerve injury completely reversed the drop in mechanical withdrawal threshold seen one week after injury and increased thermal withdrawal latency above baseline values (Figure 5). Thus, antagonists such as **18i** with dual activity at GluK1 and NMDARs may have utility in the treatment of neuropathic pain.

Compounds with similar potency as antagonists of GluK1 and NMDARs may have advantages over compounds with either activity alone. For instance, NMDARs and GluK1 containing KARs are known to be involved in pain transmission, epilepsy and in neuronal cell death and dual antagonists may have advantages in the treatment of these disorders,

such as improved therapeutic ratios. Intriguingly, with these compounds, it may be possible to simultaneously optimize both the NMDAR and KAR subtype selectivity appropriate for treating a condition such as neuropathic pain.

In summary, we have identified compounds that could be developed into GluN2D or GluK1 selective antagonists and these may be useful as pharmacological tools to probe the physiological roles of these subunits in the central nervous system. In addition, potent dual antagonists of GluK1 and GluN2D, developed from the leads identified in this study, may have therapeutic application for the treatment of a number of neurological disorders.

Experimental Methods

Chemistry experimental

General Procedures—Melting points were determined using an Electrothermal IA9100 capillary apparatus and are uncorrected. ¹H-NMR spectra were measured on either a Jeol spectrometer at 270.18 MHz, a Jeol JNM-LA300 spectrometer at 300.53 MHz, a Jeol JNM-ECP400 spectrometer at 400.18 MHz, or a Varian 400MR spectrometer at 399.77 MHz. ¹³C-NMR spectra were recorded on either a Jeol JNM-LA300 spectrometer at 75.57 MHz, a Jeol JNM-ECP400 spectrometer at 100.63 MHz, or a Varian 400MR spectrometer at 100.52 MHz. Chemical shifts (δ) are reported in parts per million (ppm) with 3-(trimethylsilyl)propionic-2,2,3,3-d₄ acid sodium salt in D₂O, or tetramethylsilane in CDCl₃ or DMSO-*d*₆ used as internal standards. Mass spectrometry was performed in the mass spectroscopy laboratories of either the Department of Chemistry, University of Bristol, UK or the School of Chemistry, University of Southampton, UK. Elemental analyses were performed either in the microanalytical laboratories of the Department of Chemistry, University of Bristol, UK or by Medac Ltd, Chobham, UK. The purity of all novel compounds was determined by combustion analysis, which confirmed that there were ≥ 95% pure. Thin layer chromatography was performed on Merck silica gel 60 F₂₅₄ plastic sheets. Flash chromatography was performed on Merck silica gel 60 (220–440 mesh) from Fisher. For thin layer chromatography of amino acids [2 (pyridine: acetic acid: water (3: 8: 11)): 3 (n-butanol)] was utilised as the eluent. Amino acids were detected by spraying plates with a 2% solution of ninhydrin in 70% ethanol. The petroleum ether utilized in each case had a boiling point range of 40–60 °C. All anhydrous reactions were conducted under argon. All anhydrous solvents were obtained from Sigma-Aldrich, UK. (±)-**4**, **5**, **17** and **34a–h** were synthesized as described previously.⁶

General Procedure for Preparing Acid Chlorides (16c, 16d, 16h, 16i): The appropriate carboxylic acid (**7**, **15c**, **15d**, **15h**) (1.00 g) was heated under reflux with excess thionyl chloride (5 mL, 68.56 mmol) in anhydrous benzene (40 mL) or anhydrous dioxane (40 mL) under a dry argon atmosphere for up to 12 h. Once all the carboxylic acid had dissolved, the solution was allowed to cool and was subsequently evaporated to dryness under reduced pressure. The product was re-dissolved in a second aliquot of anhydrous solvent (40 mL) and this was again evaporated to dryness under reduced pressure, ensuring complete removal of any excess thionyl chloride. The acid chlorides (**16c**, **16d**, **16h**, **16i**) were used without any further purification.

General Procedure for Coupling of Acid Chlorides and cis-piperazine-2,3-dicarboxylic acid (18c, 18d, 18h, 18i): A solution of the acid chloride in anhydrous dioxane (40 mL) was added dropwise to a rapidly stirring solution of cis-piperazine-2,3-dicarboxylic acid (**17**) and NaOH (3 equiv) dissolved in water/dioxane (1:1) (40 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 2 h and then allowed to warm to room temperature and stirred for a further 4 h. The pH of the reaction mixture was adjusted to 7, diluted to twice the volume with

water, and reduced to half volume under reduced pressure. The reaction mixture was acidified to pH 3 with 2 M aqueous HCl, and the precipitate formed filtered and washed with water and then three times with hot dioxane (50 mL). The solid was re-dissolved in a minimum volume of 2 M aqueous NaOH, filtered and precipitated with 2 M aqueous HCl at a pH of 3. The resulting solid was collected by filtration, washed with water and air-dried.

(2*R,3*S**)-1-(6-Iodonaphthalene-2-carbonyl)piperazine-2,3-dicarboxylic acid (18c):** **15c** (1.00 g, 3.36 mmol) and thionyl chloride were reacted in anhydrous benzene. The resulting acid chloride **16c** (1.06 g, 3.36 mmol) in anhydrous dioxane and cis-piperazine-2,3-dicarboxylic acid (**17**) (646 mg, 3.36 mmol) and sodium hydroxide (403 mg, 10.08 mmol) in water/dioxane (1:1) afforded **18c** as a white solid (272 mg, 18%); mp: 205–209 °C (dec); ¹H NMR (400 MHz, D₂O/NaOD, pH 11) δ 2.43–2.64 (m, 1H), 2.67–2.85 (m, 1H), 2.92–3.05 (m, 1H), 3.14 (d, *J* = 3.6 Hz, 0.5H), 3.20 (d, *J* = 3.6 Hz, 0.5H), 3.32 (d, *J* = 13.6 Hz, 0.5H), 4.17 (dt, *J* = 13.6, 1.6 Hz, 0.5H), 4.56 (d, *J* = 3.6 Hz, 0.5H), 5.35 (d, *J* = 3.6 Hz, 0.5 Hz), 7.33–7.43 (m, 1H), 7.44–7.54 (m, 1H), 7.55–7.71 (m, 2H), 7.76 (s, 0.5H), 7.83 (s, 0.5H), 8.06–8.13 (m, 0.5H), 8.15 (s, 0.5H); MS (ES[−]) *m/z*: 453 (M - H, 100); Anal. (C₁₇H₁₅IN₂O₅·2.06H₂O) C, H, N.

(2*R,3*S**)-1-(6-Phenylnaphthalene-2-carbonyl)piperazine-2,3-dicarboxylic acid (18d):** **15d** (1.00 g, 4.03 mmol) and thionyl chloride were reacted in anhydrous benzene. The resulting acid chloride **16d** (1.07 g, 4.03 mmol) in anhydrous dioxane and cis-piperazine-2,3-dicarboxylic acid (**17**) (774 mg, 4.03 mmol), sodium hydroxide (322 mg, 8.06 mmol) and sodium carbonate (427 mg, 4.03 mmol) in water/dioxane (1:1) afforded **18d** as an off-white solid (455 mg, 28%); mp: 198–202 °C (dec); ¹H NMR (270 MHz, D₂O/NaOD, pH 11) δ 2.81–2.84 (m, 1H), 2.85–3.07 (m, 1H), 3.09–3.27 (m, 1H), 3.31 (d, *J* = 3.5 Hz, 0.5H), 3.38 (d, *J* = 3.5 Hz, 0.5H), 3.52–3.64 (m, 0.5H), 4.29–4.41 (m, 0.5H), 4.79 (usp, 0.5H), 5.54 (d, *J* = 3.0 Hz, 0.5H), 7.41–7.50 (m, 1H), 7.51–7.64 (m, 3H), 7.79–7.87 (m, 2H), 7.88–7.95 (m, 1H), 8.02–8.11 (m, 3H), 8.19–8.24 (m, 1H); MS (ES[−]) *m/z*: 403 (M - H, 100); Anal. (C₂₃H₂₀N₂O₅·2.88H₂O) C, H, N.

(2*R,3*S**)-1-(9-Bromophenanthrene-3-carbonyl)piperazine-2,3-dicarboxylic acid (18h):** **15h** (1.00 g, 3.32 mmol) and thionyl chloride were reacted in anhydrous benzene. The resulting acid chloride **16h** (1.06 g, 3.32 mmol) in anhydrous dioxane and cis-piperazine-2,3-dicarboxylic acid (**17**) (646 mg, 3.32 mmol) and sodium hydroxide (398 mg, 9.96 mmol) in water/dioxane (1:1) afforded the monosodium salt of **18h** as an off-white solid (696 mg, 44%); mp: 232–237 °C (dec); ¹H NMR (400 MHz, D₂O/NaOD, pH 11) δ 2.15–2.28 (m, 0.5H), 2.47–2.59 (m, 0.5H), 2.71–2.84 (m, 0.5H), 3.00–3.31 (m, 2H), 3.35 (d, *J* = 13.8 Hz, 0.5H), 3.42 (d, *J* = 3.6 Hz, 0.5H), 4.39 (d, *J* = 13.8 Hz, 0.5H), 4.91 (d, *J* = 3.6 Hz, 0.5H), 5.60 (d, *J* = 3.6 Hz, 0.5H), 6.43–6.68 (m, 2H), 6.86 (s, 1H), 7.04 (s, 1H), 7.12 (s, 1H), 7.45 (s, 1H), 7.82 (s, 1H), 7.94 (s, 1H); MS (ES[−]) *m/z*: 457 (M - H, 100); Anal. (C₂₁H₁₆BrN₂O₅Na·1.61H₂O) C, H, N.

(2*R,3*S**)-1-(9-Iodophenanthrene-3-carbonyl)piperazine-2,3-dicarboxylic acid (18i):** **7** (1.00 g, 2.87 mmol) and thionyl chloride were reacted in anhydrous benzene. The resulting acid chloride **16i** (1.05 g, 2.87 mmol) in anhydrous dioxane and cis-piperazine-2,3-dicarboxylic acid (**17**) (551 mg, 2.87 mmol) and sodium hydroxide (344 mg, 8.61 mmol) in water/dioxane (1:1) afforded **18i** as a light orange solid (457 mg, 32%); mp: 205–210 °C (dec); ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.86–3.06 (m, 1.5H), 3.64 (usp, 3H), 4.44–4.54 (m, 0.5H), 4.67–4.75 (m, 0.5H), 5.51–5.67 (m, 0.5H), 7.74–7.88 (m, 2.5H), 8.06 (dd, *J* = 8.4, 2.8 Hz, 1H), 8.13–8.21 (m, 1H), 8.67 (s, 0.5H), 8.71 (s, 0.5H), 8.79–8.97 (m, 1.5H), 9.19 (s, 0.5H), 9.35 (s, 0.5H); MS (ES[−]) *m/z*: 503 (M - H, 100); Anal. (C₂₁H₁₇IN₂O₅·2.06H₂O) C, H, N.

(-)-1-(Phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid (S)-(-)-1-phenylethylamine salt (30): (S)-(-)-1-Phenylethylamine (**32**) (3.40 mL, 26.44 mmol) was added to a stirred suspension of (±)-**4** (5.00 g, 13.22 mmol) in water/dioxane (1:1, 100 mL) and the resultant solution allowed to stir for 30 mins at room temperature. Concentration in vacuo afforded a white solid, which was suspended in acetone (30 mL), stirred for 10 mins and then filtered to afford a white powder. This was crystallised from boiling water (200 mL) with dioxane being added slowly to the boiling solution until the solid had dissolved (approximately 25 mL). The solution was filtered whilst hot and then allowed to stand at room temperature overnight. **30** formed as white crystals which were filtered off and then crystallised a further 3 times until a constant optical rotation was obtained (4.03 g, 61%); $[\alpha]^{23}_D = -136^\circ$ (c 0.25, dioxane/H₂O 1:1); MS (ES⁻) m/z: 377 (M - H, 100); Anal. (C₂₉H₂₉N₃O₅·2.31H₂O) C, H, N;

(-)-1-(Phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid ((-)-4): 30 (1.00 g, 2.00 mmol) was suspended in THF/water (1:1, 100 mL) and acidified to pH 1 using 2 M aqueous HCl. The THF was removed in vacuo leading to the formation of a white precipitate which was filtered off and washed copiously with cold water. The solid was suspended in ethanol (15 mL) and stirred at room temperature for 10 mins. Filtration afforded (-)-**4** as a white solid which was washed with cold ethanol and diethyl ether and then air dried (607 mg, 80%); $[\alpha]^{23}_D = -104^\circ$ (c 0.25, DMSO); mp: 215–221 °C (dec); ¹H NMR (270 MHz, D₂O/NaOD, pH 11) δ 2.59–3.35 (m, 3H), 3.37 (d, *J* = 3.6 Hz, 0.5H), 3.45 (d, *J* = 3.6 Hz, 0.5H), 3.59 (d, *J* = 13.9 Hz, 0.5H), 4.47 (d, *J* = 13.9 Hz, 0.5H), 4.79 (usp, 0.5H), 5.57 (d, *J* = 3.6 Hz, 0.5H), 7.55–8.00 (m, 7H), 8.47–8.71 (m, 2H); MS (ES⁻) m/z: 377 (M - H, 100); Anal. (C₂₁H₁₇N₂O₅Na·1.51H₂O) C, H, N.

(+)-1-(Phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid (R)-(+)-1-phenylethylamine salt (31): (R)-(+)-1-Phenylethylamine (**33**) (3.40 mL, 26.44 mmol) was added to a stirred suspension of (±)-**4** (5.00 g, 13.22 mmol) in water/dioxane (1:1, 100 mL). The resultant solution was allowed to stir at room temperature overnight during which time a white solid precipitated from solution. This was filtered off and washed with water and then acetone. The solid was crystallised from boiling water (200 mL) with dioxane being added slowly to the boiling solution until the solid had dissolved (approx 10 mL). The solution was filtered hot and then allowed to stand at room temperature overnight. **31** formed as a white solid which was filtered off and then crystallised a further 2 times until a constant optical rotation was obtained (4.42 g, 67%); $[\alpha]^{23}_D = +152^\circ$ (c 0.25, dioxane/H₂O 1:1); MS (ES⁻) m/z: 377 (M - H, 100); Anal. (C₂₉H₂₉N₃O₅·2.18H₂O) C, H, N.

(+)-1-(Phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid ((+)-4): 31 (1.00 g, 2.00 mmol) was suspended in THF/water (1:1, 50 mL) and acidified to pH 1 using 2 M aqueous HCl. The resultant solution was stirred for 5 mins before the pH was adjusted to 3 using 1 M aqueous LiOH. The THF was then removed in vacuo leading to the formation of a white precipitate which was filtered off and washed copiously with cold water followed by ethanol and diethyl ether. Air drying afforded (+)-**4** as a white solid (685 mg, 91%); $[\alpha]^{23}_D = +108^\circ$ (c 0.25, DMSO); mp: 207–213 °C (dec); ¹H NMR (270 MHz, D₂O/NaOD, pH 11) δ 2.48–2.64 (m, 1H), 2.71–2.87 (m, 1H), 2.93–3.23 (m, 1.5H), 3.30–3.45 (m, 1.5H), 4.37 (d, *J* = 13.0 Hz, 0.5H), 4.79 (usp, 0.5H), 5.54 (d, *J* = 3.5 Hz, 0.5H), 7.49–7.63 (m, 4H), 7.65–7.71 (m, 1H), 7.73–7.84 (m, 1H), 7.86 (d, *J* = 1.6 Hz, 0.5H), 8.00 (d, *J* = 1.6 Hz, 0.5H), 8.38–8.44 (m, 0.5H), 8.46 (d, *J* = 8.6 Hz, 0.5H), 8.50–8.56 (m, 0.5H), 8.62 (d, *J* = 8.6 Hz, 0.5H); MS (ES⁻) m/z: 377 (M - H, 100); Anal. (C₂₁H₁₇N₂O₅Na·2.58H₂O) C, H, N.

Modeling studies

The X-ray crystal structure of **11** (Figure 1) in complex with the LBD of rat GluK1 (PDB code 2F34)²⁴ was used for docking experiments. The structures of the ligands used in docking experiments were built with Maestro, a module of the Schrödinger molecular modelling suite and energy minimised using the MMF94s force field in MacroModel. In all cases carboxylic acids were built in the negatively charged form and the secondary amine was positively charged. Docking of the ligands into the LBD of GluK1 was carried out using the Induced Fit workflow within Maestro, which carries out an initial docking using Glide, followed by side chain optimisation within 5 angstroms of ligand poses with Prime and then a more precise Glide docking in XP mode.²⁵ The centroid of **12** (Figure 1) in the LBD of GluK1 was used to obtain the box center for grid setup to enable Glide docking of ligands into GluK1. All other settings in the InducedFit workflow were left at default and the final Glide docking was carried out in XP mode. Ligand poses shown in Figure 3 were prepared using Accelrys DS Visualizer 2.0 (Accelrys, Inc, San Diego, USA).

Biology Experimental

Electrophysiological assays using recombinant rat NMDAR subtypes—

Electrophysiological responses were measured using a standard two-microelectrode voltage clamp as previously described.³² The voltage clamp used was a Warner Instruments (Hamden, CT, U.S.A.) model OC-725B Oocyte Clamp, designed to provide fast clamp of large cells. The recording buffer contained 116 mM NaCl, 2 mM KCl, 0.3 mM BaCl₂ and 5 mM HEPES, pH 7.4. Response magnitude was determined by the steady plateau response elicited by bath application of 10 μ M L-glutamate plus 10 μ M glycine at a holding potential of -60 mV. The presence of a plateau response was taken as an indication of the lack of significant activation of the endogenous Cl⁻ current by Ba²⁺ in these cells. Antagonist inhibition curves were fit (GraphPad Prism, ISI Software, San Diego, CA, U.S.A.) according to the equation $I = I_{\max} - I_{\max}/[1 + (IC_{50}/A)^n]$, where $I_{\max}$ is the current response in the absence of antagonist, A is the antagonist concentration and IC₅₀ is the antagonist concentration producing half-maximal inhibition. Apparent K_i values were determined by correcting for agonist affinity according to the equation $K_i = IC_{50}(\text{obs})/1 + ([\text{agonist}]/EC_{50})$ as described.³³

Calcium fluorescence assays using recombinant human KAR subtypes—The previously characterized HEK293 cell lines stably expressing GluK1(Q)³⁴ or GluK2(Q)³⁵ containing homomeric KARs were used for calcium fluorescence assays. To address the possibility that changes in receptor expression levels over time could influence experimentally determined IC₅₀ values, the EC₅₀ value for L-glutamate and the IC₅₀ values for routinely used control antagonists such as **9** (Figure 1) were continuously monitored, and no significant drift in these values was ever observed. Additionally, cells were never passaged more than 20 times.

Cell growth and ion influx studies using a Flexstation (Molecular Devices, Inc., Sunnyvale, CA, U.S.A.) were carried out in the presence of concanavalin A exactly as described previously.¹⁵ A range of concentrations of the test compound were prepared in assay buffer containing concanavalin A. During the first run, the plate reader added the test compound, buffer (control wells for subsequent L-glutamate application), or L-glutamate (to obtain a dose-response curve to L-glutamate). During the second run, L-glutamate plus antagonist was added to give a final L-glutamate concentration of either 10 μ M (GluK2) or 30 μ M (GluK1).

Concentration-response curves were analyzed using GraphPad Prism 3.02 software (San Diego, CA), with slope factor fixed at 1, and top and bottom fixed at 100% and 0%

inhibition, respectively. The dissociation constant (K_B) was calculated according to the Cheng-Prusoff equation³⁶ from the IC_{50} value for inhibiting L-glutamate-induced calcium influx.

Electrophysiological assays using recombinant human KAR subtypes—

Recombinant homomeric KARs containing either GluK1, GluK2 or GluK3 subunits were stably expressed in HEK293 cells.^{34,35,37} Cells were incubated at 37°C in Dulbecco's modified eagle medium (DMEM; Sigma, Gillingham, UK) supplemented with 2 mM L-glutamine, 10% foetal calf serum, penicillin and streptomycin and plated onto glass coverslips. Cells were then plated onto glass coverslips, 1–3 days before experiments.

Coverslips plated with HEK293 cells were placed in the experimental chamber and perfused with HEPES buffer solution (HBS) (in mM; 145 NaCl, 2 KCl, 2 MgCl₂, 2 CaCl₂, 10 glucose, 10 HEPES, pH 7.4, 320 mOsm/L) at 20°C. Patch pipettes were pulled at 1.5–3.5 MΩ and filled with intracellular solution (in mM; 130 CsCH₃SO₃, 2 NaCl, 2 MgCl₂, 10 EGTA, 10 HEPES, 4 Na₂ATP, 0.1 spermine, pH 7.2, 315 mOsm/L). Whole cell patch clamping was performed on single cells, voltage clamped at –70mV. Cells were then carefully lifted up from the coverslip and placed into the flow of the upper barrel of a theta tube, supplying HBS. The lower barrel supplied 30 mM glutamate. The theta tube was connected to a piezo device, positioned so that its sideways movement would immerse the cell in the glutamate flow for 100 ms. Recordings were taken every 20 s. When the glutamate response had stabilised, 6 recordings were made and averaged, and then an antagonist was applied through both barrels of the theta tube, dissolved to the same concentration in both the HBS and the glutamate. When the drug was in equilibrium, 6 recordings were made and averaged and then the solutions switched back to the original solutions to determine the wash off time of the drug. The current set allows 5 concentrations of the drug to be tested on each cell, allowing a dose-response curve to be generated for each cell. Antagonists were applied for approximately 2 min or until the response stabilised. Exchange of solutions was complete in 20–40 s.

Electrophysiological assay on native AMPARs expressed in the hippocampus

—Field excitatory postsynaptic potentials (fEPSPs) recordings were performed on transverse rat hippocampal slices (400 μm) using standard technique.³⁸ Briefly, slices were perfused with extracellular solution containing (mM): NaCl, 124; KCl, 3; NaH₂PO₄, 1.25; MgSO₄, 1; NaHCO₃, 26; D-glucose, 10–15; CaCl₂, 2; at 29°C. Recordings were made using microelectrodes containing 3M NaCl. Synaptic responses were evoked by stimulation of the dentate granule cell layer (mossy fiber pathway) at a baseline interval of 60 s. Data were collected and analysed on-line using the WinLTP software (www.ltp-program.com)³⁹. The fEPSPs were signal averaged every 2 min and the slope between 20 and 80% of maximum was measured and plotted on-line.

Binding assays on wildtype and point mutated GluK3—Mutagenesis was carried out on human GluK3a encoding cDNAs using the QuikChange XL Site-Directed Mutagenesis kit from Stratagene (La Jolla, CA, U.S.A.) according to the manufacturer's protocol. All residue numbering excludes the signal peptide. All mutants were verified by full-length sequencing (Geneservice, Oxford, UK).

HEK293 cells were maintained in Dulbecco's modified Eagle's medium (Sigma, Gillingham, UK) supplemented with 10% (v/v) fetal calf serum (Invitrogen Ltd., Paisley, UK), 2 mM L-glutamine, 50 U/ml penicillin, and 50 μg/ml streptomycin (all from Invitrogen Ltd., Paisley, UK) at 37°C in a humidified atmosphere of 5% CO₂. Cells were transiently transfected using linear polyethylenimine (PEI; molecular weight ~25,000; Polysciences,

Warrington, PA).⁴⁰ In brief, DNA and PEI were mixed in 150 mM NaCl at an N/P ratio of 5:8, incubated for 20 min, and added drop-wise to cells.

For membrane binding assays, 10 µg of DNA was mixed with 40 µl of PEI (1 mg/ml) in 500 µl of NaCl (150 mM), added to cells in a 175cm² flask, and incubated for 48 h. HEK 293 cells stably transfected with GluK3 were grown in the presence of 0.2 mg/ml hygromycin B (Invitrogen) as described previously.^{34,35,37}

Membrane fractions were prepared from both stably and transiently transfected cells harvested in hypotonic solution (10 mM NaHCO₃ and complete protease inhibitor cocktail; Roche Diagnostics GmbH, Mannheim, Germany) and disrupted using sonication (2 × 10 s bursts at 10 W, with 20 s incubation on ice in between). Cell homogenates were then spun at 1,000g for 20 min at 4°C to remove cellular debris. Membranes were pelleted at 40,000g for 20 min at 4°C and washed three times by resuspension in binding buffer (50 mM Tris, buffered with citric acid, pH 7.4) and centrifugation (40,000g, 20 min, 4°C). After the measurement of protein concentrations using the Bio-Rad protein assay kit (Bio-Rad Laboratories, Hemel Hempstead, UK), membrane fractions were separated into aliquots, snap-frozen in liquid nitrogen, and stored at -80°C. Ligand binding to wildtype and point mutated GluK3 was determined in a filtration binding assay using a Brandel cell harvester (model M-30; Brandel, Gaithersburg, MD) as described previously.⁴¹ Competition binding assays were run with 20 nM [³H]kainate and 1 mM kainate to determine non-specific binding. Kainate was obtained from Ascent Scientific (Avonmouth, UK). [³H]Kainate was purchased from PerkinElmer Life and Analytical Sciences. Data was analysed using GraphPad Prism version 3.02 (San Diego, CA).

Effect of 18i on nociceptive behaviour in rats—Nociceptive behavioural testing was performed on 10 male Wistar rats (~250 g). These were kept on a standard 12:12 hour light:dark cycle and fed standard chow and water ad libitum. All experimental procedures were carried out in accordance with the United Kingdom Animals (Scientific Procedures) Act 1986, and with the approval of the University of Bristol Ethical Review Panel.

Nerve Injury Surgery—All Wistar rats underwent surgery for nerve injury (PSNI).²⁷ Anaesthesia was induced using ~3% isoflurane in oxygen, and maintained with ~2% isoflurane in oxygen. Animals were maintained are flexive throughout surgery.

A ~1 cm incision was made along the inguinal fossa region (from mid thigh to below knee). Blunt dissection was used to remove superficial connective tissue and the saphenous nerve was isolated from muscle and vasculature with fine forceps. The saphenous nerve was split and ~50% tightly ligated using sterile 4.0 silk suture. The incision was sutured with sterile 4.0 silk suture and animals allowed to recover.

Nociceptive Behaviour—Rats were habituated to the testing environment the day prior to testing. All animals underwent an habituation period (10 minutes) prior to each testing session. Nociceptive testing was carried out after injection of **18i** in normal animals prior to saphenous nerve injury, and in the same animals once behavioural hypersensitivity had developed, seven days after PSNI.

Mechanical withdrawal thresholds were measured using calibrated Von Frey (vF) hairs as previously described.²⁷ vF hairs were applied to the plantar surface of the hindpaw for maximum of five seconds or until the animal withdrew from the stimulus. Each vF hair was applied a total of five times to each hindpaw and both left and right hindpaws were tested. Stimulus:response curves were constructed and threshold values calculated from these curves.

Standard thermal withdrawal latencies were determined after mechanical nociceptive testing.⁴² The radiant heat source was positioned under the plantar surface of the hindpaw and latency to withdrawal was recorded. Both right and left hindpaws were tested, and each hindpaw was stimulated a total of three times on each test occasion. A mean of the three measurements was used as the withdrawal latency.

Drug or vehicle (n=5/group) was administered via intraperitoneal injection and animals were left for 15 min before nociceptive testing began.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors would like to thank the NIH (grant number MH60252), the BBSRC (grant BB/F012519/1) and the MRC (Grants G0601509, G0601812) for funding this work. The authors would like to thank Dr David Bleakman at Eli Lilly & Co., USA for supplying the GluK1-3 recombinant cell lines.

Abbreviations

AMPA	(S)-2-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid
AMPArs	(S)-2-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid receptors
kainate	(2S,3S,4S)-3-carboxymethyl-4-isopropenyl-pyrrolidine-2-carboxylic acid
DMEM	Dulbecco's modified eagle medium
EPSP	excitatory postsynaptic potential
fEPSP	field excitatory postsynaptic potential
HBS	4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid buffer solution
HEK293	human embryonic kidney 293
HEPES	4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid
iGluRs	ionotropic glutamate receptors
i.p.	intraperitoneal
KARs	(2S,3S,4S)-3-carboxymethyl-4-isopropenyl-pyrrolidine-2-carboxylic acid receptors
LBD	ligand binding domain
LTP	long-term potentiation
NMDA	N-methyl-D-aspartic acid
NMDAR	N-methyl-D-aspartic acid receptor
PEI	polyethylenimine
PSNI	partial saphenous nerve ligation injury
vF	Von Frey
WT	wildtype

References

1. (a) Watkins JC, Jane DE. The glutamate story. *Br J Pharmacol*. 2006; 147:S100–S108. [PubMed: 16402093] (b) Kew JNC, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. *Psychopharmacology*. 2005; 179:4–29. [PubMed: 15731895] (c) Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R. Glutamate receptor ion channels: structure, regulation, and function. *Pharmacological Reviews*. 2010; 62:405–496. [PubMed: 20716669]
2. (a) Collingridge GL, Olsen RW, Peters J, Spedding M. A nomenclature for ligand-gated ion channels. *Neuropharmacology*. 2009; 56:2–5. [PubMed: 18655795] (b) Jane DE, Lodge DL, Collingridge GL. Kainate receptors: pharmacology, function and therapeutic indications. *Neuropharmacology*. 2009; 56:90–113. [PubMed: 18793656]
3. (a) Monaghan, DT.; Jane, DE. Pharmacology of the NMDA receptor. In: VanDongen, Antonius, editor. *Biology of the NMDA receptor*. Taylor and Francis; London, UK: 2008. p. 257–282. (b) Neyton J, Pierre Paoletti P. Relating NMDA Receptor Function to Receptor Subunit Composition: Limitations of the Pharmacological Approach. *J Neurosci*. 2006; 26:1331–1333. [PubMed: 16452656]
4. Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. *Lancet Neurol*. 2008; 7:742–755. [PubMed: 18635022] (b) Hizue M, Pang CH, Yokoyama M. Involvement of N-methyl-D-aspartate-type glutamate receptor epsilon I and epsilon 4 subunits in tonic inflammatory pain and neuropathic pain. *Neuroreport*. 2005; 16:1667–1670. [PubMed: 16189474] (c) Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. *Nat Rev Drug Discov*. 2008; 7:426–437. [PubMed: 18425072]
5. (a) Buller AL, Monaghan DT. Pharmacological heterogeneity of NMDA receptors: Characterization of NR1a/NR2D heteromers expressed in *Xenopus* oocytes. *European Journal of Pharmacology*. 1997; 320:87–94. [PubMed: 9049607] (b) Feng B, Tse HW, Skifter DA, Morley RM, Jane DE, Monaghan DT. Structure–activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid. *Br J Pharmacol*. 2004; 141:508–516. [PubMed: 14718249] (c) Costa BM, Feng B, Tsintsadze TS, Morley RM, Irvine MW, Tsintsadze VP, Lozovaya NA, Jane DE, Monaghan DT. NMDA receptor NR2 subunit selectivity of a series of novel piperazine-2,3-dicarboxylate derivatives; preferential blockade of extrasynaptic NMDA receptors in the rat hippocampal CA3-CA1 synapse. *J Pharmacol Exp Ther*. 2009; 331:618–626. [PubMed: 19684252]
6. Morley RM, Tse H-W, Feng B, Miller JC, Monaghan DT, Jane DE. Synthesis and pharmacology of *N*¹-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. *J Med Chem*. 2005; 48:2627–2637. [PubMed: 15801853]
7. Fischer G, Mutel V, Trube G, Malherbe P, Kew JN, Mohacsi E, Heitz MP, Kemp JA. Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. *J Pharmacol Exp Ther*. 1997; 283:1285–1292. [PubMed: 9400004]
8. Costa BM, Irvine MW, Fang G, Eaves RJ, Mayo-Martin MB, Skifter DA, Monaghan DT, Jane DE. A novel family of negative and positive allosteric modulators of NMDA receptors. *J Pharmacol Exp Ther*. 2010; 2010(335):614–621. [PubMed: 20858708]
9. Mosley CA, Acker TM, Hansen KB, Mullasseril P, Andersen KT, Le P, Vellano KM, Bräuner-Osborne H, Liotta DC, Traynelis SF. Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-methyl-D-aspartate receptor antagonists. *J Med Chem*. 2010; 53:5476–5490. [PubMed: 20684595]
10. Sheardown M, Nielsen E, Hansen A, Jacobsen P, Honore T. 2,3-Dihydroxy-6-nitro-7-sulphamoyl-benzo(F)quinoxaline: A neuroprotectant for cerebral ischemia. *Science*. 1990; 247:571–574. [PubMed: 2154034]
11. (a) Clarke VR, Ballyk BA, Hoo KH, Mandelzys A, Pellizzari A, Bath CP, Thomas J, Sharpe EF, Davies CH, Ornstein PL, Schoepp DD, Kamboj RK, Collingridge GL, Lodge D, Bleakman D. A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. *Nature*. 1997; 389:599–603. [PubMed: 9335499] (b) Vignes M, Clarke VR, Parry MJ, Bleakman D, Lodge D, Ornstein PL, Collingridge GL. The GluR5 subtype of kainate receptor regulates excitatory synaptic transmission in areas CA1 and CA3 of the rat hippocampus. *Neuropharmacology*. 1998;

- 37:1269–1277. [PubMed: 9849664] (c) Bortolotto ZA, Clarke VR, Delany CM, Parry MC, Smolders I, Vignes M, Ho KH, Miu P, Brinton BT, Fantáske R, Ogden A, Gates M, Ornstein PL, Lodge D, Bleakman D, Collingridge GL. Kainate receptors are involved in synaptic plasticity. *Nature*. 1999; 402:297–301. [PubMed: 10580501] (d) Filla SA, Winter MA, Johnson KW, Bleakman D, Bell MG, Bleisch TJ, Castano AM, Clemens-Smith A, Del Prado M, Dieckman DK, Dominguez E, Escribano A, Ho KH, Hudziak KJ, Katofiasc MA, Martinez-Perez JA, Mateo A, Mathes BM, Mattiuz EL, Ogden AML, Phebus LA, Stack DR, Stratford RE, Ornstein PL. Ethyl (3*S*,4*aR*,6*S*,8*aR*)-6-(4-ethoxycarbonylimidazol-1-ylmethyl)decahydroisoquinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine. *J Med Chem*. 2002; 45:4383–4386. [PubMed: 12238915] (e) Dominguez E, Iyengar S, Shannon HE, Bleakman D, Alt A, Arnold BM, Bell MG, Bleisch TJ, Buckmaster JL, Castano AM, Prado MD, Escribano A, Filla SA, Ho KH, Hudziak KJ, Jones CK, Martinez-Perez JA, Mateo A, Mathes BM, Mattiuz EL, Ogden AML, Simmons RMA, Stack DR, Stratford RE, Winter MA, Wu Z, Ornstein PL. Two prodrugs of potent and selective GluR5 kainate receptor antagonists active in three animal models of pain. *J Med Chem*. 2005; 48:4200–4203. [PubMed: 15974569] (f) Weiss B, Alt A, Ogden AM, Gates M, Dieckman DK, Clemens-Smith A, Ho KH, Jarvie K, Rizkalla G, Wright RA, Calligaro DO, Schoepp D, Mattiuz EL, Stratford RE, Johnson B, Salhoff C, Katofiasc M, Phebus LA, Schenck K, Cohen M, Filla SA, Ornstein PL, Johnson KW, Bleakman D. Pharmacological characterization of the competitive GLU_{K5} receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo. *J Pharmacol Exp Ther*. 2006; 318:772–781. [PubMed: 16690725]
12. (a) O'Neill MJ, Bond A, Ornstein PL, Ward MA, Hicks CA, Hoo K, Bleakman D, Logde D. Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia. *Neuropharmacology*. 1998; 37:1211–1222. [PubMed: 9849659] (b) Simmons RMA, Li DL, Hoo KH, Deverill M, Ornstein PL, Iyengar S. Kainate GluR5 receptor mediates the nociceptive response to formalin in the rat. *Neuropharmacology*. 1998; 37:25–36. [PubMed: 9680256] (c) O'Neill MJ, Bogaert L, Hicks CA, Bond A, Ward MA, Ebinger G, Ornstein PL, Michotte Y, Lodge D. LY377770, a novel iGluR5 kainate receptor antagonist with neuroprotective effects in global and focal cerebral ischaemia. *Neuropharmacology*. 2000; 39:1575–1588. [PubMed: 10854902] (d) Smolders I, Bortolotto ZA, Clarke VRJ, Warre R, Khan GM, O'Neill MJ, Ornstein PL, Bleakman D, Ogden A, Weiss B, Stables JP, Ho KH, Ebinger G, Collingridge GL, Lodge D, Michotte Y. Antagonists of GLU_{K5}-containing kainate receptors prevent pilocarpine-induced limbic seizures. *Nature Neuroscience*. 2002; 5:796–804.
 13. Perrais D, Pinheiro PS, Jane DE, Mulle C. Antagonism of recombinant and native GluR7-containing kainate receptors. *Neuropharmacology*. 2009; 56:131–140. [PubMed: 18761361]
 14. (a) Dolman NP, Troop HM, More JCA, Alt AJ, Ogden AM, Jones S, Morley RM, Roberts PJ, Bleakman D, Collingridge GL, Jane DE. Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors. *J Med Chem*. 2005; 48:7867–7881. [PubMed: 16302825] (b) Dolman NP, More JCA, Alt A, Ogden AM, Troop HM, Bleakman D, Collingridge GL, Jane DE. Structure-activity relationship studies on N³-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists. *J Med Chem*. 2006; 49:2579–2592. [PubMed: 16610801]
 15. More JCA, Nistico R, Dolman NP, Clarke VRJ, Alt AJ, Ogden AM, Buelens FP, Troop HM, Kelland EE, Pilato F, Bleakman D, Bortolotto ZA, Collingridge GL, Jane DE. Characterisation of UBP296; a novel, potent and selective kainate receptor antagonist. *Neuropharmacology*. 2004; 47:46–64. [PubMed: 15165833]
 16. Evans RH, Evans SJ, Pook DC, Sunter DC. A comparison of excitatory amino acid antagonists acting at primary afferent C fibres and motoneurons of the isolated spinal cord of the rat. *Br J Pharmacol*. 1987; 91:531–537. [PubMed: 3038242]
 17. Wendt MD, Rockway TW, Geyer A, McClellan W, Weitzberg M, Zhao X, Mantei R, Nienaber VL, Stewart K, Klinghofer V, Giranda VL. Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of *N*-Phenyl amide 6-substitution. *J Med Chem*. 2004; 47:303–324. [PubMed: 14711304]

18. Summers JB, Mazdiyasni H, Holms JH, Ratajczyk JD, Dyer RD, Carter GW. Hydroxamic acid inhibitors of 5-lipoxygenase. *J Med Chem.* 1987; 30:574–580. [PubMed: 3820229]
19. Adcock W, Wells PR. Substituent effects in naphthalene. *Aust J Chem.* 1965; 18:1351–1364.
20. Schultz J, Goldberg MA, Ordas EP, Carsch G. Attempts to find new antimalarials. XI. Derivatives of Phenanthrene, III. Amino alcohols derived from 9-chlorophenanthrene. *J Org Chem.* 1946; 11:320–328. [PubMed: 20279685]
21. Mosettig E, Van de Kamp J. Studies in the phenanthrene series. II. Phenanthrene carboxylic acids and 9-bromophenanthrene derivatives. *J Am Chem Soc.* 1932; 54:3328–3337.
22. Klapars A, Buchwald SL. Copper-catalyzed halogen exchange in aryl halides: An aromatic Finkelstein reaction. *J Am Chem Soc.* 2002; 124:14844–14845. [PubMed: 12475315]
23. Kinarsky L, Feng B, Skifter D, Morley RM, Sherman S, Jane DE, Monaghan DT. Identification of subunit-specific and antagonist-specific amino acids in the NMDA receptor glutamate binding pocket. *J Pharm Exp Ther.* 2005; 313:1066–1074.
24. Mayer ML, Ghosal A, Dolman NP, Jane DE. Crystal structures of the kainate receptor GluR5 ligand binding core dimer complex with novel selective antagonists. *J Neurosci.* 2006; 26:2852–2861. [PubMed: 16540562]
25. Schrödinger Suite 2010 Induced Fit Docking protocol; Glide version 5.6, Schrödinger, LLC, New York, NY, 2010; Prime version 2.2. Schrödinger, LLC; New York, NY: 2010.
26. Alushin GM, Jane DE, Mayer ML. Binding site and ligand flexibility revealed by high resolution crystal structures of GluK1 competitive antagonists. *Neuropharmacology.* 2011; 60:126–134. [PubMed: 20558186]
27. Hulse R, Wynick D, Donaldson LF. Characterisation of a novel neuropathic pain model in mice. *Neuroreport.* 2008; 19:825–829. [PubMed: 18463495]
28. Pook P, Brugger F, Hawkins NS, Clark KC, Watkins JC, Evans RH. A comparison of the actions of agonists and antagonists at non-NMDA receptors of C fibres and motoneurons of the immature rat spinal cord in vitro. *Br J Pharmacol.* 1993; 108:179–184. [PubMed: 8094024]
29. (a) Bettler B, Boulter J, Hermans-Borgmeyer I, O'Shea-Greenfield A, Deneris ES, Moll C, Borgmeyer U, Hollman M, Heinemann S. Cloning of a novel glutamate receptor subunit, GluR5: expression in the central nervous system during development. *Neuron.* 1990; 5:583–595. [PubMed: 1977421] (b) Wilding TJ, Huettner JE. Functional diversity and developmental changes in rat neuronal kainate receptors. *J Physiol.* 2001; 532.2:411–421. [PubMed: 11306660] (c) Kerchner GA, Wilding TJ, Huettner JE, Zhuo M. Kainate receptor subunits underlying presynaptic regulation of transmitter release in the dorsal horn. *J Neurosci.* 2002; 22:8010–8017. [PubMed: 12223554]
30. Atlason PT, Scholefield CL, Eaves RJ, Mayo-Martin MB, Jane DE, Molnár E. Mapping the ligand binding sites of kainate receptors: molecular determinants of subunit-selective binding of the antagonist [³H]UBP310. *Mol Pharm.* 2010; 78:1036–1045.
31. Lucifora S, Willcockson HH, Lu CR, Darstein M, Phend KD, Valtschanoff JG, Rustioni A. Presynaptic low- and high-affinity kainate receptors in nociceptive spinal afferents. *Pain.* 2006; 120:97–105. [PubMed: 16360275]
32. Buller AL, Larson HC, Schneider BE, Beaton JA, Morrisett RA, Monaghan DT. The molecular basis of NMDA receptor subtypes: native receptor diversity is predicted by subunit composition. *J Neurosci.* 1994; 14:5471–5484. [PubMed: 7916045]
33. Durand GM, Gregor P, Zheng X, Bennett MV, Uhl GR, Zukin RS. Cloning of an apparent splice variant of the rat N-methyl-D-aspartate receptor NMDAR1 with altered sensitivity to polyamines and activators of protein kinase C. *Proc Natl Acad Sci USA.* 1992; 89:9359–9363. [PubMed: 1409641]
34. Korczak B, Nutt SL, Fletcher EJ, Hoo KH, Elliott CE, Rampersad V, McWhinnie EA, Kamboj RK. cDNA cloning and functional properties of human glutamate receptor EAA3 (GluR5) in homomeric and heteromeric configuration. *Recept Chann.* 1995; 3:41–49.
35. Hoo KH, Nutt SL, Fletcher EJ, Elliott CE, Korczak B, Deverill RM, Rampersad V, Fantaske RP, Kamboj RK. Functional expression and pharmacological characterization of the human EAA4 (GluR6) glutamate receptor: a kainate selective channel subunit. *Recept Chann.* 1994; 2:327–337.

36. Cheng YC, Prusoff WH. Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 per cent inhibition (IC_{50}) of an enzymatic reaction. *Biochem Pharmacol.* 1973; 22:3099–3108. [PubMed: 4202581]
37. Nutt SL, Hoo KH, Rampersad V, Deverill RM, Elliott CE, Fletcher EJ, Adams SL, Korczak B, Foldes RL, Kamboj RK. Molecular characterization of human EAA5 (GluR7) receptor: a high-affinity kainate receptor with novel potential RNA editing sites. *Recept Chann.* 1994; 2:315–326.
38. Bortolotto ZA, Amici M, Anderson WW, Isaac JT, Collingridge GL. Synaptic plasticity in the hippocampal slice preparation. *Curr Protoc Neurosci.* 2011; Chapter 6(Unit 6.13)
39. Anderson WW, Collingridge GL. Capabilities of the WinLTP data acquisition program extending beyond basic LTP experimental functions. *J Neurosci Methods.* 2007; 162:346–356. [PubMed: 17306885]
40. Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. *Nucleic Acid Res.* 2002; 30:E9. [PubMed: 11788735]
41. Molnár E, Baude A, Richmond SA, Patel PB, Somogyi P, McIlhinney RAJ. Biochemical and immunocytochemical characterization of antipeptide antibodies to a cloned GluR1 glutamate receptor subunit: Cellular and subcellular distribution in the rat forebrain. *Neuroscience.* 1993; 53:307–326. [PubMed: 8492909]
42. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. *Pain.* 1988; 32:77–88. [PubMed: 3340425]

Figure 1.
Structures of known NMDAR and KAR antagonists

Figure 2.

A. Concentration response curves for the antagonist activity of **18i** in electrophysiological assays on recombinant human GluK1 (■), GluK2 (●), GluK3 (▲) KAR subunits expressed in HEK293 cells. IC₅₀ values were estimated to be 0.65 μM (95% confidence intervals: 0.27 μM – 1.7 μM, *n*=1–6) for GluK1, > 100 μM (*n*=2) for GluK2 and 81.3 μM (95% confidence intervals: 40.5 μM – 163 μM, *n*=3–8) for GluK3. **B.** Pooled data showing the lack of effect of **18i** (100 μM) on AMPAR mediated synaptic transmission at mossy fiber synapses following 30 min of perfusion. There was no significant difference (*P*=0.68, student's *t* test) between the control response (100 ± 2%) and the response in the presence of **18i** (99 ± 2%). Data are expressed as % of slope (mean ± s.e.m., *n*=4). The inserted traces are averages of 4 successive responses obtained under (a) control conditions and (b) in the presence of **18i**. Stimulus artefact has been removed for clarification.

Figure 3. Interactions of ligands with the LBD of GluK1. **A:** 2*S*,3*R* isomer of **4**, **B:** **18c**, **C:** **18i**. **D:** Solvent accessible surfaces have been calculated for both the LBD of GluK1 and **18i** to show that the ligand is an antagonist of GluK1 because it prevents closure of the ligand binding domain due to the presence of the bulky aromatic substituent.

Figure 4.

An alanine residue (A660) is a major determinant of the insensitivity of GluK3 to **18i**. In competition binding assays **18i** (100 μM, 300 μM, 1 mM) inhibited [³H]kainate (20 nM) binding to wildtype (WT) GluK3 less potently than binding to the GluK3 A660S mutant receptor (data from 3 separate experiments, each performed in triplicate, mean ± s.e.m). Data obtained for 300 μM **18i** are significantly different for WT GluK3 and GluK3 A660S mutant ($P < 0.05$, student's t test).

Figure 5.

A. 18i reversed nerve injury induced nociceptive behaviour.

Male Wistar rats developed significant ipsilateral, but no contralateral mechanical allodynia 3 days after PSNI (nerve injury), compared to baseline (# $p < 0.01$ and & $p < 0.001$ compared to baseline values, one way ANOVA, $n = 5$ per group). Acute administration of 30 mg/kg **18i** i.p. up to 1 hour prior to testing on day 7 (vertical arrow) reversed the allodynia in comparison to vehicle administration ($***p < 0.001$, two way ANOVA, $n = 5$ per group). **B.** Animals with PNSI do not develop thermal hypersensitivity following nerve injury. Acute treatment with **18i** prior to testing on day 7 (arrow) led to an increase in withdrawal latency to radiant heat ($**p < 0.01$, two way ANOVA, $n = 5$ per group). All data are shown as mean $\pm$ s.e.m.

Scheme 1^a

^aReagents and conditions: (a) (i) SOCl₂, C₆H₆ or dioxane, reflux, 12 h; (b) 3 equiv NaOH, dioxane/H₂O (2:1), 0°C, 2 h and then rt, 4 h, (iii) 2 M HCl (aq)

Scheme 2^a

^aReagents and conditions: (a) (i) LiOH, H₂O, rt, 4h, (ii) 2 M HCl (aq); (b) (i) 10% Pd/C, H₂, NaOH, H₂O, rt, 18 h, (ii) 2 M HCl (aq)

Scheme 3^a

^aReagents and conditions: (a) NaI, CuI, N,N'-dimethylethylenediamine, dioxane, 110°C, 65 h; (b) (i) KOH, dioxane, 70°C, 2h, (ii) 2 M HCl (aq); (c) Ph-B(OH)₂, K₂CO₃, Pd(PPh₃)₄, toluene/ethanol/water (4:1:2), 80°C, 18h; (d) (i) NaOH, THF/H₂O, 70°C, 2h, (ii) 2 M HCl (aq)

^aReagents and conditions: (a) Phenylacetylene, CuI, PdCl₂(PPh₃)₂, TBAF, THF, rt, 18 h; (b) (i) Br₂, NaOH, dioxane, 70°C, 1 h, (ii) conc H₂SO₄

Scheme 4^a

^aReagents and conditions: (a) (i) Br_2 , NaOH , dioxane, 70°C , 1 h, (ii) conc HCl (aq); (b) NaI , CuI , $\text{N,N}'$ -dimethylethylenediamine, dioxane, 110°C , 65 h; (c) (i) Br_2 , NaOH , dioxane, 70°C , 1 h, (ii) conc HCl (aq)

Scheme 5^a

^aReagents and conditions: (a) (i) (*S*)-(-)-1-phenethylamine (**32**), dioxane/H₂O (1:1), rt, 30 mins, (ii) crystallisation (dioxan/water); (b) (i) (*R*)-(+)-1-phenylethylamine (**33**), dioxane/H₂O (1:1), rt, 18 h, (ii) crystallisation (dioxan/water); (c) THF/H₂O, 2 M HCl (aq)

Table 1

Summary of the activity of piperazine-2,3-dicarboxylic acid derivatives at recombinant NMDAR and KAR subtypes^a

Compound	Formula	n	A	R ¹	NMDAR [K _i , μM] (n≥4) ^b				KAR [K _B , μM] (n=3) ^c	
					GluN2A	GluN2B	GluN2C	GluN2D	GluK1	GluK2
34a ^d	A	0	-	H	9.6 ± 1.1	18.2 ± 1.3	3.9 ± 0.1	9.3 ± 0.4	45.6 ± 11.5	ND
18a	A	0	-	F	7.4 ± 1.5	12.3 ± 0.9	3.6 ± 0.1	5.1 ± 0.1	52.9 ± 3.9	ND
18b	A	0	-	Br	4.1 ± 0.3	2.7 ± 0.2	2.1 ± 0.1	2.2 ± 0.1	16.2 ± 3.6	ND
18c	A	0	-	I	3.0 ± 0.2	1.3 ± 0.1	1.8 ± 0.1	1.6 ± 0.1	7.5 ± 1.4	>100
18d	A	0	-	Ph	>100 ^e	>100 ^e	5.1 ± 0.1	2.4 ± 0.1	5.8 ± 1.5	>100
18f	A	2	-	H	5.1 ± 0.5	2.3 ± 0.2	4.1 ± 0.3	2.7 ± 0.2	67.8 ± 5.2	ND
19	A	0	-	CO ₂ H	>100 ^f	>100 ^f	>100 ^f	>100 ^f	59.7 ± 2.0	ND
34b ^d	B	-	CO	H	15.7 ± 0.4	5.0 ± 0.3	9.0 ± 0.2	4.3 ± 0.1	9.8 ± 1.4	>100
34c ^d	B	-	SO ₂	H	13.6 ± 1.8	16.2 ± 4.1	8.7 ± 0.6	10.9 ± 0.5	>100	ND
20	B	-	CO	CO ₂ H	ND	>100 ^g	>100 ^g	ND	51.5 ± 18.7	ND
18k	C	-	C≡C	-	138 ± 9	24.1 ± 1.1	21.4 ± 0.4	10.5 ± 1.3	13.4 ± 3.3	>100
18l	C	-	N=N	-	99.3 ± 7.0	12.9 ± 1.4	28.0 ± 1.0	10.8 ± 0.3	14.2 ± 3.1	>100
21	C	-	(CH ₂) ₂	-	>100 ^h	>100 ^h	>100 ^h	>100 ^h	16.7 ± 3.4	ND

^a Abbreviations: ND = not determined

^b K_i values (μM) for inhibiting the responses of recombinant rat NMDA receptors (GluN1 expressed with the appropriate GluN2 subunit) expressed in *Xenopus* oocytes (means ± s.e.m.). For compounds with activities listed as >100 this refers to the IC₅₀ value.

^c K_B values for antagonism of glutamate-stimulated Ca²⁺ influx in HEK293 cells expressing either human GluK1 or GluK2 (means ± s.e.m.). For compounds with activities listed as >100 this refers to the K_B value.

^dData for NMDA activity taken from ref 6.

^e $30.3 \pm 8.2\%$ and $37.1 \pm 5.0\%$ antagonism of GluN2A and GluN2B, respectively at a concentration of $100 \mu\text{M}$ of **18d**.

^fLess than 5% antagonism of GluN2A-D at a concentration of $100 \mu\text{M}$ of **19**.

^gLess than 15% antagonism of GluN2B and GluN2C at a concentration of $100 \mu\text{M}$ of **20**.

^h $11.50 \pm 2.25\%$, $>5\%$, $29.12 \pm 1.00\%$ and $10.25 \pm 1.03\%$ antagonism of GluN2A, GluN2B, GluN2C and GluN2D, respectively at a concentration of $100 \mu\text{M}$ of **21**.

Table 2

Activity of piperazine-2,3-dicarboxylic acid derivatives at recombinant NMDAR and KAR subtypes^a

Compound	Formula	A	R ¹	NMDAR [K _B , μM](n≥4) ^b				KAR [K _B , μM] (n=3) ^c	
				GluN2A	GluN2B	GluN2C	GluN2D	GluK1	GluK2
5^d	A	-	H	22.0 ± 1.4	17.2 ± 1.2	5.2 ± 0.5	2.4 ± 0.1	14.2 ± 3.4	>100
18^g	A	-	Cl	7.2 ± 0.7	15.2 ± 2.6	3.2 ± 0.2	1.7 ± 0.1	21.8 ± 6.0	ND
18^h	A	-	Br	11.5 ± 0.8	8.0 ± 0.4	2.8 ± 0.1	1.2 ± 0.1	12.8 ± 2.1	>100
18ⁱ	A	-	I	7.4 ± 0.9	3.8 ± 0.9	1.9 ± 0.2	1.0 ± 0.1	4.8 ± 1.1	>100
18^j	-	-	-	10.5 ± 2.6	5.2 ± 0.5	3.4 ± 0.4	2.5 ± 0.3	14.4 ± 1.8	>100
(±)-4^d	B	CO	H	0.55 ± 0.15	0.31 ± 0.02	0.10 ± 0.01	0.13 ± 0.04	7.5 ± 1.4	>100
(-)-4	B	CO	H	0.21 ± 0.02	0.22 ± 0.04	0.07 ± 0.01	0.09 ± 0.01	3.0 ± 0.7	>100
(+)-4	B	CO	H	17.6 ± 2.1	13.5 ± 1.0	3.4 ± 0.3	4.6 ± 0.2	82.0 ± 18.2	ND
34^{d,e}	B	CO	H	10.5 ± 1.2	9.1 ± 1.0	4.9 ± 0.6	6.0 ± 2.0	59.2 ± 19.6	ND
34^{e,d}	B	CO	Br	0.32 ± 0.01	0.25 ± 0.02	0.10 ± 0.01	0.15 ± 0.01	8.0 ± 2.1	>100
34^{f,d}	B	CH ₂	H	11.2 ± 1.3	10.3 ± 1.9	2.7 ± 0.1	3.2 ± 0.2	39.0 ± 10.0	ND
34^{g,d}	C	-	H	1.5 ± 0.1	0.76 ± 0.11	0.29 ± 0.02	0.57 ± 0.03	14.1 ± 1.6	>100
34^{h,d}	C	-	Br	3.9 ± 0.2	2.2 ± 0.3	0.66 ± 0.07	1.0 ± 0.1	11.5 ± 3.0	ND

^a Abbreviations: ND = Not determined

^b K_B values (μM) for inhibiting the responses of recombinant rat NMDA (GluN1 expressed with the appropriate GluN2 subunit) receptors expressed in *Xenopus* oocytes (means ± s.e.m.). For compounds with activities listed as >100 this refers to the IC₅₀ value.

^c K_B values for antagonism of glutamate-stimulated Ca²⁺ influx in HEK293 cells expressing either human GluK1 or GluK2 (means ± s.e.m.). For compounds with activities listed as >100 this refers to the K_B value. ND = not determined.

^d Data for NMDA receptor antagonist activity taken from ref 6.

^eCompound **34d** is the racemic trans isomer of **4**.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript